2023 Fall Clinical Virtual Grand Rounds
2023 Virtual Grand Rounds Session 2: March 1, 2023 - Optimizing Photodynamic Therapy in Your Practice Today for Better Actinic Keratosis Outcomes Tomorrow
About
Fall Clinical Virtual Grand Rounds consists of regularly scheduled CME sessions on a variety of dermatological diseases and tools, delivered by the top experts in dermatology.
Please join us for this week's session:
Wednesday, March 1, 2023
8 PM ET/ 5 PM PT
Optimizing Photodynamic Therapy in Your Practice Today for Better Actinic Keratosis Outcomes Tomorrow
This activity is supported by an educational grant from Biofrontera
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
March 1, 2023
March 1, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Describe the key data on photodynamic therapy to manage actinic keratosis
Identify patients with actinic keratosis for photodynamic therapy
Discuss strategies to optimize care of patients with actinic keratosis with photodynamic therapy
Intended Audience
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Edward (Ted) Lain, MD, MBA
Chief Medical Officer Dermatologist
Sanova Dermatology
Austin, TX
Dawn Merrit, DO
Dermatology Residency Program Director
OhioHealth Riverside Hospital
Columbus, OH
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen
Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel
Advisory Board: Almirall, Biofrontera, SUN
Grant/Research Support: Almirall, Biofrontera
Speaker's Bureau: Almirall
Consultant: Abbvie, Arcutis, BMS, Dermavant, Lilly, Novartis,UCB
Speaker's Bureau or Honoraria: Abbvie, Amgen, BMS, Dermavent, LEO, Lilly, Pfizer
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.